Trial Information
Oral ST1481 in Adults With Malignant Glioma: a Phase I-II Clinical Trial
Inclusion Criteria
Inclusion criteria:
- Histologically confirmed diagnosis of a recurrent primary malignant glioma
- Life expectancy of at least 3 months with normal hematological, liver and renal
function
Exclusion criteria:
- Pregnant and lactating patients
- Participation in any investigating drug study within 4 weeks preceding treatment
start or concurrent treatment with any other anti-cancer therapy
- Gastrointestinal dysfunction that could alter absorption or motility
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Authority:
United States: Food and Drug Administration
Study ID:
ST 01-402
NCT ID:
NCT00032903
Start Date:
March 2002
Completion Date:
October 2005
Related Keywords:
- Malignant Glioma
- Malignant Glioma, Camptothecin, Pharmacokinetics
- Glioma
Name | Location |
Rhode Island Hospital |
Providence, Rhode Island 02903 |